June 13, 2024

Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. May 06, 2026

    Corcept Must Face Most Teva Mifepristone Antitrust Claims

    A California federal judge on Tuesday once again mostly refused to throw out Teva Pharmaceuticals' claims that Corcept Therapeutics used patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol disorder treatment, finding that at this stage in the litigation the allegations are adequate.

3 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS